What did AdAlta (ASX:1AD) achieve in its clinical trial?

AdAlta (ASX:1AD) reported that a trial participant reached two years of cancer survival with complete tumour clearance following treatment with lead CAR-T cell therapy EW-001. A second patient also reached one year of survival after receiving the treatment.

What were the complete response rates for AdAlta (ASX:1AD)?

AdAlta (ASX:1AD) achieved a 14% complete response rate across all 14 evaluable patients in the trial. The complete response rate reached 20% among the 10 patients treated with higher doses of EW-001.

How did the market react to the update from AdAlta (ASX:1AD)?

Following the announcement, the AdAlta (ASX:1AD) share price remained unchanged at $0.003.

What are the upcoming manufacturing and regulatory milestones for AdAlta (ASX:1AD)?

AdAlta (ASX:1AD) plans to complete the transfer of EW-001 manufacturing to Cell Therapies Pty Ltd in Australia. The company also expects to conduct a pre-IND meeting with the US FDA in the second half of CY2026.

What is the primary focus of AdAlta (ASX:1AD)?

AdAlta (ASX:1AD) is a Melbourne-based biotechnology company that develops cellular immunotherapies for solid cancers. Its lead therapy, EW-001, was formerly designated as BZDS1901 and is being evaluated in an ongoing trial in China.

Health

Image for illustrative purposes only. Not a real photo.

AdAlta reports two year cancer survival milestone

Written by Jon CuthbertPublished Aug 5, 2026, 12:25 AM

AdAlta recorded two-year cancer clearance in a patient during its lead CAR-T trial.
AdAlta shares remained unchanged at $0.003 following the clinical update.
The company plans to advance manufacturing transfers and engage with US regulators in 2026.

Biotechnology firm AdAlta (ASX:1AD) reported that a trial patient achieved two years of recurrence-free cancer survival.

Published second-line therapies for advanced mesothelioma typically report complete tumour clearance rates of 0%.

The treatment generated complete responses in 14% of overall participants and 20% of higher-dose patients.

AdAlta stated that manufacturing is transferring to Cell Therapies Pty Ltd ahead of US regulatory filings.

Following the announcement, the AdAlta share price was unchanged at $0.003.

The Melbourne-based biotech company specialises in developing cellular immunotherapies to target solid cancers.

The ongoing clinical study in China evaluates the CAR-T cell therapy formerly designated as BZDS1901.

Frequently asked questions

Health

7 months ago

AdAlta and AdCella join Shanghai Cell Therapy to develop CAR-T cancer treatment

AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have announced a major global collaboration with Shanghai Cell Therapy Group to co-develop the first-in-class CAR-T therapy, BZDS1901, for markets outside Greater China.

Frequently asked questions

What did AdAlta (ASX:1AD) achieve in its clinical trial?

What were the complete response rates for AdAlta (ASX:1AD)?

How did the market react to the update from AdAlta (ASX:1AD)?

What are the upcoming manufacturing and regulatory milestones for AdAlta (ASX:1AD)?

What is the primary focus of AdAlta (ASX:1AD)?

Frequently asked questions

What did AdAlta (ASX:1AD) achieve in its clinical trial?

What were the complete response rates for AdAlta (ASX:1AD)?

How did the market react to the update from AdAlta (ASX:1AD)?

What are the upcoming manufacturing and regulatory milestones for AdAlta (ASX:1AD)?

What is the primary focus of AdAlta (ASX:1AD)?

Related news

AdAlta and AdCella join Shanghai Cell Therapy to develop CAR-T cancer treatment

Related news

AdAlta and AdCella join Shanghai Cell Therapy to develop CAR-T cancer treatment

Assets related to this article